ClinicalTrials.gg
CompletedNCT00616434Updated Aug 13, 2014Results posted

A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis

A Phase 2 interventional study of BG9418 (Interferon beta-1a) and Placebo in Active Ulcerative Colitis, sponsored by Biogen. Completed at 36 sites in 7 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-08-13.

Sponsored by Biogen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies in Colitis, Ulcerative with a site in Russian Federation — 2 open to participants now, 2 under way, none of them phase 3. Colitis, Ulcerative · Russian Federation.

Enrollment
51st of 70
123 · median 284
Started
2008
with 2 others
Phase 2
31 of 73
none open now
Registered
10th of 73
by date

Among the 73 studies in Colitis, Ulcerative with a site in Russian Federation, this one is the 51st largest by enrollment of the 70 interventional ones that give a count, is one of 3 that started in 2008, is one of 31 in phase 2, and was the 10th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

2 of the 73 studies in Colitis, Ulcerative with a site in Russian Federation are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Colitis, Ulcerative with a site in Russian Federation, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the clinical activity of interferon beta-1a in participants with moderate to severe ulcerative colitis (UC). Secondary objectives of this study are to determine (i) the safety and tolerability of interferon beta-1a in participants with moderate to severe UC, and (ii) the percentage of participants, with a decrease in the Simple Clinical Colitis Activity Index (SCCAI) score of ≥3 points at Week 8.

03

Conditions studied

  • Active Ulcerative Colitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Established diagnosis of ulcerative colitis (UC) for ≥6 months

    • 20 cm active disease at Screening endoscopy
  • Must have active UC with a Mayo Score/Disease Activity Index (DAI) of 6 to 13 points and moderate to severe disease on endoscopy (Mayo endoscopic score of at least 2) despite prior or concomitant treatment
  • Colonoscopy within past 5 years for extent of disease and to exclude polyps
  • For subjects with UC for more than 10 years, colonoscopy with appropriate within 1 year prior to Screening to exclude dysplasia and neoplasia.
  • Must be willing and able to practice effective during the study and for 1 month after the last dose of study treatment.

Key Exclusion Criteria:

  • Diagnosis of indeterminate colitis or Crohn's disease
  • Need for imminent surgery
  • Diagnosis of primary sclerosing cholangitis or toxic megacolon
  • ≤9 g/dL
  • White blood cell count \< 3500 cells/mm\^3
  • Lymphocyte count \<1000 cells/µL
  • count \<100,000 cells/µL
  • Female subjects who are pregnant or who wish to become pregnant during the study, or who are lactating
  • Known symptomatic colonic stricture
  • Stool cultures positive for enteric infection
  • History of malignant disease
  • History of major abdominal surgery (e.g., gastrectomy) within past 5 years
  • History of small bowel or colonic obstruction or resection
  • History of drug or alcohol abuse (as defined by the Investigator) within 2 years prior to Screening
  • Use of anti-diarrheal agents during the screening period
  • Previous participation in this study
  • Previous treatment with interferon beta or other interferon products

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
123 participants (actual)

Study arms

  • Experimental
    Interferon beta-1a

    Interferon beta-1a 30 µg intramuscular (IM) injection twice weekly for 12 weeks

    Drug: BG9418 (Interferon beta-1a)

  • Placebo comparator
    Placebo

    Placebo IM injection twice weekly for 12 weeks

    Drug: Placebo

Interventions

  • Avonex IM injection, self-administered per protocol

    Also known as: Avonex®

  • DrugPlacebo

    Placebo IM injection, self-administered per protocol.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Clinical Response

    Clinical response is defined as a decrease from baseline in the total Mayo score of at least 3 points and at least 30%, accompanied by a decrease in the subscore for rectal bleeding of at least 1 point or an absolute subscore of 1 or less. Baseline was defined as the score collected during the screening period. The Mayo Score/Disease Activity Index (DAI) measures disease activity through assessment of 4 items: stool frequency, rectal bleeding, endoscopy findings, and Physician Global Assessment (PGA). Each item of the score is assessed on a 4-point scale, 0, 1, 2, or 3, with a higher score representing greater severity. In this study, the endoscopy subscore was expanded to a 5-point scale to increase sensitivity in this important dimension of the disease (0=normal/inactive disease, 4=deep ulceration). The Total Mayo Score can therefore range from 0 to13 points.

    Time frame: Baseline and Week 8

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE, can therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. All AE's were analyzed based on the principle of treatment emergence. An AE was regarded as treatment-emergent if it was not present prior to receiving the first injection but subsequently appeared, or if it was present prior to receiving the first injection and subsequently worsened in severity.

    Time frame: Up to 16 weeks

  2. Percentage of Participants With a Decrease on Simple Clinical Colitis Activity Index (SCCAI) of ≥3 Points at Week 8

    The SCCAI measures disease activity as defined by both participants and examiners and includes the following 13 items: general well-being, abdominal pain, bowel frequency, stool consistency, bleeding, anorexia, nausea or vomiting, abdominal tenderness, extra-intestinal complications (eye, mouth, joint, skin), temperature, sigmoidoscopic assessment, nocturnal bowel movements, and urgency of defecation. Scores range from 0 to 19 points, and scores \<2.5 have been shown to correlate with Patient-Defined Remission, and a decrease of \>1.5 points from Baseline correlates with Patient-Defined Significant Improvement. Baseline is defined as the mean of the screening and visit 1 scores.

    Time frame: Baseline and Week 8

07

Results

Posted Aug 13, 2014

Participant flow

Participant flow — Overall Study
MilestoneInterferon Beta-1aPlacebo
Started6261
Completed5653
Not completed68
Withdrew: Adverse event52
Withdrew: Physician decision04
Withdrew: Withdrawal by subject11
Withdrew: Protocol deviation01

Outcome measures

PrimaryPercentage of Participants With a Clinical Response

Clinical response is defined as a decrease from baseline in the total Mayo score of at least 3 points and at least 30%, accompanied by a decrease in the subscore for rectal bleeding of at least 1 point or an absolute subscore of 1 or less. Baseline was defined as the score collected during the screening period. The Mayo Score/Disease Activity Index (DAI) measures disease activity through assessment of 4 items: stool frequency, rectal bleeding, endoscopy findings, and Physician Global Assessment (PGA). Each item of the score is assessed on a 4-point scale, 0, 1, 2, or 3, with a higher score representing greater severity. In this study, the endoscopy subscore was expanded to a 5-point scale to increase sensitivity in this important dimension of the disease (0=normal/inactive disease, 4=deep ulceration). The Total Mayo Score can therefore range from 0 to13 points.

Time frame:
Baseline and Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With a Clinical Response
percentage of participantsInterferon Beta-1aPlacebo
Percentage of Participants With a Clinical Response5344
SecondaryNumber of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE, can therefore, be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. All AE's were analyzed based on the principle of treatment emergence. An AE was regarded as treatment-emergent if it was not present prior to receiving the first injection but subsequently appeared, or if it was present prior to receiving the first injection and subsequently worsened in severity.

Time frame:
Up to 16 weeks
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsInterferon Beta-1aPlacebo
Number of Participants With Adverse Events (AEs)5235
SecondaryPercentage of Participants With a Decrease on Simple Clinical Colitis Activity Index (SCCAI) of ≥3 Points at Week 8

The SCCAI measures disease activity as defined by both participants and examiners and includes the following 13 items: general well-being, abdominal pain, bowel frequency, stool consistency, bleeding, anorexia, nausea or vomiting, abdominal tenderness, extra-intestinal complications (eye, mouth, joint, skin), temperature, sigmoidoscopic assessment, nocturnal bowel movements, and urgency of defecation. Scores range from 0 to 19 points, and scores \<2.5 have been shown to correlate with Patient-Defined Remission, and a decrease of \>1.5 points from Baseline correlates with Patient-Defined Significant Improvement. Baseline is defined as the mean of the screening and visit 1 scores.

Time frame:
Baseline and Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With a Decrease on Simple Clinical Colitis Activity Index (SCCAI) of ≥3 Points at Week 8
percentage of participantsInterferon Beta-1aPlacebo
Percentage of Participants With a Decrease on Simple Clinical Colitis Activity Index (SCCAI) of ≥3 Points at Week 86446

Adverse events

Collected over Up to 16 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Interferon Beta-1a—1/62 (1.6%)44/62 (71%)
Placebo—3/61 (4.9%)20/61 (32.8%)
Most frequent serious events
Most frequent serious events
EventInterferon Beta-1aPlacebo
Colitis UlcerativeGastrointestinal disorders1/622/61
Tibia FractureInjury, poisoning and procedural complications0/621/61
Most frequent other events
Most frequent other events
EventInterferon Beta-1aPlacebo
Influenza Like IllnessGeneral disorders25/626/61
HeadacheNervous system disorders11/623/61
PyrexiaGeneral disorders8/622/61
AnaemiaBlood and lymphatic system disorders1/626/61
Colitis UlcerativeGastrointestinal disorders5/624/61
MyalgiaMusculoskeletal and connective tissue disorders4/620/61
Upper Respiratory Tract InfectionInfections and infestations3/620/61
HypertensionVascular disorders3/620/61
MalaiseGeneral disorders3/621/61

Baseline characteristics

Age, Continuous
Age, Continuous(years)Interferon Beta-1aPlaceboTotal
Mean41.1 (21 to 64)41.0 (20 to 65)41.0 (20 to 65)
Sex: Female, Male
Sex: Female, Male(Participants)Interferon Beta-1aPlaceboTotal
Female192645
Male433578
08

Study locations

36 sites
  • Investigator
    Birmingham, Alabama 35294, United States
  • Investigator
    Lakewood, Colorado 80215, United States
  • Investigator
    Bristol, Connecticut 06010, United States
  • Investigator
    Wellesley Hills, Massachusetts 02481, United States
  • Investigator
    Oklahoma City, Oklahoma 73104, United States
  • Investigator
    Calgary, Alberta T2N4N1, Canada
  • Investigator
    Kelowna, British Columbia V1Y 2H4, Canada
  • Investigator
    Winnipeg, Manitoba R3A1R9, Canada
  • Investigator
    Hradec Kralove, Czech Republic
  • Investigator
    Ostrava, Czech Republic
  • Investigator
    Parbudice, Czech Republic
  • Investigator
    Praha 4, Czech Republic
  • Investigator
    Praha 7, Czech Republic
  • Investigator
    Slany, Czech Republic
  • Investigator
    Teplice, Czech Republic
  • Investigator
    Budapest, Hungary
  • Investigator
    Eger, Hungary
  • Investigator
    Szeged, Hungary
  • Investigator
    Szekesfehervar, Hungary
  • Investigator
    Lublin, Poland
  • Investigator
    Pruszkow, Poland
  • Investigator
    Sopot, Poland
  • Investigator
    Torun, Poland
  • Investigator
    Warszawa, Poland
  • Investigator
    Wroclaw, Poland
  • Investigator
    Kazan, Russian Federation
  • Investigator
    Krasnodar, Russian Federation
  • Investigator
    Lipetsk, Russian Federation
  • Investigator
    Moscow, Russian Federation
  • Investigator
    Nizhniy Novgorod, Russian Federation
  • Investigator
    Rostov-on-Don, Russian Federation
  • Investigator
    Saratov, Russian Federation
  • Investigator
    St. Petersburg, Russian Federation
  • Investiator
    Yaroslavl, Russian Federation
  • Investigator
    Nitra, Slovakia
  • Investigator
    Trencin, Slovakia
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 4 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2008
First posted
Feb 15, 2008
Start
May 2008
Primary completionActual
Mar 2010
CompletionActual
Mar 2010
Results first posted
Aug 13, 2014
Last update
Aug 13, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00616434
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Feb 15, 2008
Start date
May 2008
Primary completion
Mar 2010
Completion
Mar 2010
Results posted
Aug 13, 2014
Last update
Aug 13, 2014

Study contacts

Medical Director
study director · Biogen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interferon beta-1a

Start the discussion